S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

TVTX Travere Therapeutics Inc

6.08

0.55 (9.95%)

May 01 2024 - Closed

Delayed by 15 minutes

Travere Therapeutics EPS misses by $0.25, misses on revenue

To read the full story on Seeking Alpha, click here.

Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Travere Therapeutics Charts.

Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Travere Therapeutics Charts.

Travere Therapeutics Inc News

Travere Therapeutics to Report First Quarter 2024 Financial Results
Monday 29 April 2024 (2 days ago) • GlobeNewswire Inc.

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Wednesday 24 April 2024 (1 week ago) • GlobeNewswire Inc.

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Wednesday 24 April 2024 (1 week ago) • PR Newswire (Canada)

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Thursday 4 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Wednesday 3 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 13 March 2024 (2 months ago) • GlobeNewswire Inc.

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.

Travere Therapeutics to Present at Upcoming Investor Conferences
Monday 26 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Friday 23 February 2024 (2 months ago) • GlobeNewswire Inc.

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
Friday 23 February 2024 (2 months ago) • PR Newswire (US)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Tuesday 20 February 2024 (2 months ago) • Edgar (US Regulatory)

More Travere Therapeutics Inc News Articles

Global Developments (PK)

FBEC Worldwide (PK)

Mullen Automotive

Atacama Resources (PK)

NaturalShrimp (QB)

NioCorp Developments

Branded Legacy (PK)

International Star (PK)

MicroCloud Hologram

Fannie Mae (QB)

Tonner One World (PK)

Moon Equity (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions